Cyclo Therapeutics Recognizes Niemann-Pick Disease Awareness Month Highlighting Need for Broader Awareness and Support for Research to Find a Treatment
October 19 2021 - 9:15AM
Business Wire
Company engaged in ongoing initiatives to help
raise awareness and provide information on research and support for
patients and families
Cyclo Therapeutics, Inc. (Nasdaq: CYTH), a clinical stage
biotechnology company dedicated to developing life-changing
medicines through science and innovation for patients and families
living with diseases, today joins with the global Niemann-Pick
Disease community in recognizing Niemann-Pick Disease Awareness
Month, an initiative to build broader awareness of the impact this
disease has on patients, families, and caregivers across the
globe.
“As a company dedicated to advancing research to develop a
treatment for Niemann-Pick Disease Type C (NPC), we are honored to
commemorate Niemann-Pick Disease Awareness Month and join with the
entire community in reinforcing the critical need for broader
disease awareness, more services for families and caregivers, and
support for research that can lead to the first approved therapy in
the U.S. for a community in desperate need of treatment options,”
said Scott Fine, CEO of Cyclo Therapeutics. “We also acknowledge
the many leaders from the NPC community who have joined in efforts
to share their stories and have made the important decision to
participate in clinical research.”
NPC is a rare, progressive and fatal genetic disorder
characterized by abnormal accumulation of cholesterol in cells.
Symptoms of the disease include enlarged liver or spleen,
difficulties with motor skills, speech, swallowing and feeding as
well as cognitive impairment.
In honor of Niemann-Pick Disease Awareness Month, Cyclo
Therapeutics will be engaging in several initiatives to help raise
awareness and provide information on research and support for
patients and families. These include:
- Participation in an informational webinar in collaboration with
the National Niemann-Pick Disease Foundation (NNPDF) to provide an
update on the Company’s pivotal Phase 3 clinical trial,
TransportNPC™, that is currently enrolling patients at treatment
centers in the U.S. and around the world. A replay of this event is
available at www.nnpdf.org.
- The launch of NPCspotlight.com, a new website with information
about the disease and perspectives from patients and others about
living with NPC.
- A community newsletter with updates on progress in the
Company’s research efforts.
“We have heard from so many patients and families about how much
they need a treatment to be available for NPC, and Niemann-Pick
Disease Awareness Month is an important time to renew our focus on
moving promising research forward,” said Lisa Kjems, MD, PhD, the
Company’s Chief Medical Officer. “We are very grateful to all of
the patients and families who are supporting our efforts to develop
a treatment for NPC. Their bravery and dedication inspire our work
every day.”
About Niemann-Pick Disease Type C1 (NPC)
NPC is a rare genetic disease affecting 1 in 100,000 live births
globally. Approximately 95% of individuals with NPC have mutations
in the NPC1 gene and 5% have mutations in the NPC2 gene. NPC
affects nearly every cell in the body due to a deficiency in either
the NPC1 or NPC2 protein, which are required for the transport and
processing of cholesterol within the cell. As cholesterol
accumulates within cells, NPC causes symptoms that affect the
brain, liver, spleen, lung, and other organs and often leads to
premature death.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology
company dedicated to developing life-changing medicines through
science and innovation for patients and families suffering from
disease. The Company’s Trappsol® Cyclo™, an orphan drug designated
product in the United States and Europe, is the subject of four
formal clinical trials for Niemann-Pick Disease Type C, a rare and
fatal genetic disease, (www.ClinicalTrials.gov NCT02939547,
NCT02912793, NCT03893071 and NCT04860960). The Company is planning
an early phase clinical trial using Trappsol® Cyclo™ intravenously
in Alzheimer’s Disease based on encouraging data from an Expanded
Access program for late-onset Alzheimer’s Disease (NCT03624842).
Additional indications for the active ingredient in Trappsol®
Cyclo™ are in development. For additional information, visit the
Company’s website: www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains “forward-looking statements” about
the company’s current expectations about future results,
performance, prospects and opportunities, including, without
limitation, statements regarding the satisfaction of closing
conditions relating to the offering and the anticipated use of
proceeds from the offering. Statements that are not historical
facts, such as “anticipates,” “believes” and “expects” or similar
expressions, are forward-looking statements. These statements are
subject to a number of risks, uncertainties and other factors that
could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The
factors which may influence the company’s future performance
include the company’s ability to obtain additional capital to
expand operations as planned, success in achieving regulatory
approval for clinical protocols, enrollment of adequate numbers of
patients in clinical trials, unforeseen difficulties in showing
efficacy of the company’s biopharmaceutical products, success in
attracting additional customers and profitable contracts, and
regulatory risks associated with producing pharmaceutical grade and
food products. These and other risk factors are described from time
to time in the company’s filings with the Securities and Exchange
Commission, including, but not limited to, the company’s reports on
Forms 10-K and 10-Q. Unless required by law, the company assumes no
obligation to update or revise any forward-looking statements as a
result of new information or future events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211019005723/en/
Investor Contact: JTC Team, LLC Jenene Thomas (833)
475-8247 CYTH@jtcir.com
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cyclo Therapeutics (NASDAQ:CYTH)
Historical Stock Chart
From Apr 2023 to Apr 2024